Expectation vs reality: Real-world lymphoma patients often excluded from trials shaping their treatment

A new study has uncovered why many patients with relapsed diffuse large B-cell lymphoma (rDLBCL) fail to respond as well as expected to newly approved cancer therapies. Patients treated with novel therapies in routine practice often experience poorer responses and greater toxicity than those reported in clinical trials.